Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | huntingtin | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | kinesin family 1 | 0.0412 | 1 | 1 |
Onchocerca volvulus | 0.0058 | 0.1033 | 0.2226 | |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0383 | 0.0564 |
Brugia malayi | hypothetical protein | 0.0286 | 0.6788 | 1 |
Schistosoma mansoni | kinesin eg-5 | 0.0054 | 0.0915 | 0.0644 |
Entamoeba histolytica | kinesin, putative | 0.0054 | 0.0915 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0383 | 0.0564 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.6788 | 0.666 |
Giardia lamblia | Kinesin-5 | 0.0054 | 0.0915 | 0.5 |
Onchocerca volvulus | Huntingtin homolog | 0.0148 | 0.3304 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0383 | 0.0564 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0383 | 0.0564 |
Plasmodium falciparum | kinesin-5 | 0.0054 | 0.0915 | 0.5 |
Schistosoma mansoni | survival motor neuron protein | 0.0058 | 0.1033 | 0.0787 |
Onchocerca volvulus | Huntingtin homolog | 0.0148 | 0.3304 | 1 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0054 | 0.0915 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 0.3304 | 0.4867 |
Brugia malayi | Iron-sulfur cluster assembly accessory protein | 0.0058 | 0.1033 | 0.1522 |
Schistosoma mansoni | hypothetical protein | 0.0058 | 0.1033 | 0.0787 |
Brugia malayi | hypothetical protein | 0.0148 | 0.3304 | 0.4867 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0383 | 0.0564 |
Brugia malayi | Kinesin motor domain containing protein | 0.0054 | 0.0915 | 0.1348 |
Loa Loa (eye worm) | kinesin-like protein KLP2 | 0.0054 | 0.0915 | 0.1348 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0368 | 0.0542 |
Plasmodium vivax | kinesin-5 | 0.0054 | 0.0915 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0359 | 0.8644 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 0.3304 | 0.4867 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.6788 | 0.666 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.6788 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 7.9433 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | 20.5878 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.